Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Blog | December 04, 2023

Amended FRE 702 on Expert Testimony Effective December 1, 2023

Blog | December 01, 2023

ITC Monthly Wrap-Up: November 2023

Blog | November 27, 2023

Minnesota Patent Litigation Wrap-Up: Q3 2023

Article | November 21, 2023

Strategic Use of Evidence at the Patent Trial and Appeal Board

Article | November 17, 2023

Why the Effect of Vivint Has Been Minimal

Blog | November 15, 2023

ITC Monthly Wrap-Up: October 2023

Blog | November 09, 2023

Legal Alert: FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book

Blog | November 03, 2023

District of Delaware Finds Allergan Patents Invalid for Lack of Written Description and Obviousness-Type Double Patenting in Allergan v. MSN Labs

Blog | November 01, 2023

Legal Alert: EPO Enlarged Board of Appeal Raises Bar for Challenging Priority Claims at the EPO

Blog | October 31, 2023

Texas Patent Litigation Monthly Wrap-Up: October 2023

Blog | October 30, 2023

District of Delaware Finds Non-Orange Book-Listed Patents Subject to the Same Pleading Standard as Listed Patents in ANDA Infringement Suit

Blog | October 17, 2023

USPTO Issues Proposed Rules on Pre-Issuance Internal Circulation and Review of PTAB Decisions